Carbohydrates as targets of immunity: their synthesis, antibody recognition and use as key vaccine components
Synthetic oligosaccharides are designed and used to identify immunodominant epitopes of bacterial polysaccharide antigens. Conjugates of the most promising oligosaccharides are developed as potential vaccines. Focus is on diarrheal diseases. Shigellosis – bacillary […]
At the forefront of the rising fields of Chemical and Synthetic Biology, CarbUniVax is a multidisciplinary project sitting at the frontier between Glycosciences and Vaccinology. A multidisciplinary strategy is proposed that challenges ambitious goals […]
Sitting at the frontier between the fields of Chemistry, Glycosciences, and Vaccinology, FlexBiVac is a multidisciplinary project aimed at demonstrating the proof of concept for a new generation of polysaccharide-based multivalent vaccines. The concept […]
A synthetic carbohydrate-based conjugate vaccine ready for a clinical trial
Drug Discovery & Screening at Institut Pasteur
The Technological Targeted Action Drug Discovery and Screening (ATC-DDS) coordinates projects and collaborations at the Institut Pasteur Paris campus on therapeutic development. It raises awareness for DDS in basic research projects and stimulates intra-campus […]
Protected tetrasaccharides, their preparation and their use in the synthesis of bacterial oligosaccharides
2022The First-in-Human Synthetic Glycan-Based Conjugate Vaccine Candidate against Shigella., ACS Cent Sci 2022 Apr; 8(4): 449-460.
2022Toward a Multivalent Synthetic Oligosaccharide-Based Conjugate Vaccine against Shigella: State-of-the-Art for a Monovalent Prototype and Challenges., Vaccines (Basel) 2022 Mar; 10(3): .
2022Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans., Anal Chem 2022 02; 94(4): 2279-2287.
2021Computer-aided engineering of a branching sucrase for the glucodiversification of a tetrasaccharide precursor of S. flexneri antigenic oligosaccharides., Sci Rep 2021 10; 11(1): 20294.
2021Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study., Lancet Infect Dis 2021 04; 21(4): 546-558.
2021Exploratory N-Protecting Group Manipulation for the Total Synthesis of Zwitterionic Shigella sonnei Oligosaccharides., Chemistry 2021 Mar; 27(18): 5694-5711.
2021Convergent Chemoenzymatic Strategy to Deliver a Diversity of Shigella flexneri Serotype-Specific O-Antigen Segments from a Unique Lightly Protected Tetrasaccharide Core., J Org Chem 2021 02; 86(3): 2058-2075.
2021Redirecting substrate regioselectivity using engineered ΔN123-GBD-CD2 branching sucrases for the production of pentasaccharide repeating units of S. flexneri 3a, 4a and 4b haptens., Sci Rep 2021 01; 11(1): 2474.
2019Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human., Hum Vaccin Immunother 2019 ; 15(6): 1338-1356.
2018ADP-heptose is a newly identified pathogen-associated molecular pattern of Shigella flexneri., EMBO Rep 2018 12; 19(12): .
+View full list of publications
Phone: +33 1 40 61 38 20
Address: Unité de Chimie des Biomolécules, Institut Pasteur, 25-28 Rue du Docteur Roux 75015, Paris France